Close Menu

Expression Pathology

Movers & Shakers


William Wallen, Jonathan Knowles, Jon Burrows, Jenny Heidbrink, Sheeno Thyparambil

The firms will combine their respective technologies to identify and measure cancer-related protein targets.

Mayo applied the technology for solubilizing and capturing the protein content in FFPE tissue to develop a mass spectrometry-based method for the diagnosis and classification of amyloidosis in routine biopsy samples in a clinical setting. It will offer its test through its reference lab.

Mayo Clinic has licensed rights to IP that will be used in its test for for diagnosing and classifying amyloidosis.

The firm also said that it and NextGen Sciences have developed a protein biomarker assay method that can provide rapid, reproducible, quantitative measurement of protein expression in formalin-fixed, paraffin-embedded tissue.

The firm will use the funds to develop protein biomarker-based personalized medicine assays.


Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.